10-Q: Zoetis Q3 2025: Revenue Up 1%, Net Income Jumps 6%

Zoetis Inc. reports a 1% increase in total revenue to $2.4 billion and a 6% rise in net income attributable to Zoetis Inc. to $721 million for the third quarter ended September 30, 2025, driven by price growth and companion animal product sales.

Summary

• Total revenue for the three months ended September 30, 2025, increased by $12 million, or 1%, to $2,400 million compared to $2,388 million in the prior year.
• Net income attributable to Zoetis Inc. for the three months ended September 30, 2025, increased by 6% to $721 million, up from $682 million in the prior year.
• Diluted earnings per share (EPS) for the three months ended September 30, 2025, was $1.63, an increase from $1.50 in the prior year.
• For the nine months ended September 30, 2025, total revenue increased by $141 million, or 2%, to $7,080 million compared to $6,939 million in the prior year.
• Net income attributable to Zoetis Inc. for the nine months ended September 30, 2025, increased by 9% to $2,070 million, up from $1,905 million in the prior year.
• Diluted EPS for the nine months ended September 30, 2025, was $4.65, an increase from $4.18 in the prior year.
• Operational revenue for the three months ended September 30, 2025, was relatively flat, with approximately 4% price growth and 1% volume growth from other in-line products, offset by a 4% volume decrease from the medicated feed additive (MFA) divestiture and a 1% volume decrease from key franchises.
• Operational revenue for the nine months ended September 30, 2025, increased by 3%, driven by approximately 4% price growth, 2% volume growth from key franchises, and 1% volume growth from other in-line products, partially offset by a 4% volume decrease from the MFA divestiture.
• Cost of sales as a percentage of revenue decreased to 28.5% in Q3 2025 from 29.4% in Q3 2024, and to 27.6% for the nine months ended September 30, 2025, from 29.0% in the prior year period.
• The effective tax rate for the three months ended September 30, 2025, was 18.7%, down from 20.8% in the prior year, primarily due to higher net discrete tax benefits.
• U.S. segment revenue decreased by 2% in Q3 2025, mainly due to a $25 million reduction in livestock products (impact of MFA divestiture), partially offset by increased companion animal product sales.
• International segment revenue increased by 3% in Q3 2025, with operational revenue growth of 1% driven by companion animal products, and a favorable foreign exchange impact of 2%.
• Dr. Robert J. Polzer, Executive Vice President and President, Research and Development, will retire effective December 31, 2025, and Dr. Kevin Esch has been appointed as his successor, effective January 1, 2026.

Sentiment

Score: 7

Explanation: The company demonstrated solid net income and EPS growth, improved margins, and strategic capital management, including a substantial share repurchase program and successful debt refinancing. Growth in companion animal products is a strong positive, offsetting some declines in livestock due to the MFA divestiture. However, modest overall revenue growth, ongoing foreign exchange headwinds, and the significant, unresolved IRS tax dispute introduce a degree of uncertainty. Overall financial health and strategic direction appear sound.

Positives

• Net income attributable to Zoetis Inc. increased by 6% for the three months ended September 30, 2025, to $721 million, and by 9% for the nine months ended September 30, 2025, to $2,070 million.
• Diluted EPS increased to $1.63 for Q3 2025 (from $1.50) and to $4.65 for the nine months ended September 30, 2025 (from $4.18).
• Strong price growth of approximately 4% contributed to revenue for both the three and nine months ended September 30, 2025.
• Cost of sales as a percentage of revenue improved, decreasing to 28.5% in Q3 2025 from 29.4% in Q3 2024, and to 27.6% for the nine months ended September 30, 2025, from 29.0% in the prior year.
• The effective tax rate for Q3 2025 was lower at 18.7% compared to 20.8% in Q3 2024, primarily due to higher net discrete tax benefits.
• U.S. companion animal revenue increased due to strong sales in parasiticides (Simparica and Revolution franchises), diagnostics, and key dermatology products.
• International companion animal operational revenue grew, driven by increased sales of parasiticides (Simparica and Revolution/Stronghold franchises), key dermatology products, and mAb products for OA pain (Librela and Solensia).
• International livestock revenue, excluding the MFA divestiture, increased across all species, with cattle and poultry sales growing due to price and demand for vaccines, and fish products growing due to increased vaccine sales in Norway and Chile.
• Net cash provided by operating activities remained robust at $2,011 million for the nine months ended September 30, 2025.
• A new $1.25 billion senior unsecured revolving credit facility was established in August 2025, expiring in August 2030, enhancing liquidity.
• Approximately $4.5 billion remains under the $6 billion share repurchase authorization as of September 30, 2025, indicating continued commitment to shareholder returns.

Negatives

• Total revenue growth was modest at 1% for the three months and 2% for the nine months ended September 30, 2025.
• Operational revenue for the three months ended September 30, 2025, was relatively flat.
• Volume decreased by approximately 4% in both periods due to the divestiture of the medicated feed additive product portfolio.
• Volume from key franchises decreased by approximately 1% in the three months ended September 30, 2025.
• U.S. livestock revenue decreased by $25 million (9%) in Q3 2025 and $128 million (17%) for the nine months ended September 30, 2025, primarily due to the MFA divestiture.
• International livestock operational revenue decreased by $13 million (3%) in Q3 2025.
• Foreign exchange unfavorably impacted reported revenue growth by approximately 1% for the nine months ended September 30, 2025.
• Net cash provided by operating activities decreased by $37 million for the nine months ended September 30, 2025, compared to the prior year.
• Net cash used in investing activities increased by $141 million for the nine months ended September 30, 2025, primarily due to capital expenditures and net payments of derivative instrument activity.
• Other (income)/deductions-net for the three months ended September 30, 2025, was negatively impacted by higher foreign currency losses.

Risks

• New or modified tariffs and other trade protection measures by the U.S. or other countries could increase raw material/component costs, impact demand, and lead to supply chain disruptions.
• Retaliatory trade policies or anti-U.S. sentiment in certain regions may lead to increased preference for local competitors or heightened regulatory scrutiny.
• Outbreaks of animal diseases may reduce regional or global sales of animal-derived food products, reduce exports, or require halting production at main sites.
• Significant portions of revenue and costs are exposed to changes in foreign exchange rates, impacting financial results and operations.
• Reliance on third-party suppliers for products, materials, and services exposes the company to availability constraints, price volatility, and supply disruptions.
• Failure to comply with extensive state, federal, and international regulations (R&D, manufacturing, marketing, sales, human health diagnostics) could result in fines, production shutdowns, product withdrawals, or legal actions.
• Inability to obtain or maintain required regulatory approvals for new or existing products, or delays in the approval process, could prevent product sales.
• International operations are subject to complex economic sanctions laws, with violations potentially leading to civil/criminal penalties, reputational harm, and operational difficulties.
• Failure to comply with environmental, health, and safety laws and regulations could result in remediation costs, loss of permits, fines, or operational curtailment.
• Evolving climate change regulations (e.g., EU ESRS/CSRD, California Climate Corporate Data Accountability Act) could result in additional compliance costs and taxes.
• Increasing focus on preventing environmental contamination from perand polyfluoroalkyl substances (PFAS) could lead to reporting, restriction, or phase-out requirements for products or packaging.
• The company is currently under IRS audit for tax years 2017 and 2018, with a proposed additional tax liability of approximately $450 million for 2018, the outcome of which is uncertain and could materially affect financial statements.
• Quarterly financial results are subject to variability from tariffs, macroeconomic conditions, competitive dynamics, geopolitical tensions, inflation, global supply chain disruption, distributor inventory, weather patterns, herd management decisions, regulatory actions, disease outbreaks, product and geographic mix, timing of price increases, and investment decisions.
• Competition from existing and generic alternative products could impact product sales and profitability.
• Unanticipated safety, quality, or efficacy concerns about products could lead to recalls or decreased sales.
• Consolidation of customers and distributors could impact market access and pricing power.
• Disruptive innovations and advances in medical practices and technologies could render existing products obsolete.
• Failure to successfully acquire businesses, license rights, integrate operations, or divest businesses could hinder strategic growth.
• Restrictions and bans on the use of antibacterials in food-producing animals could negatively impact livestock product sales.
• Inability to hire and retain executive officers and other key personnel could disrupt operations and strategic execution.
• Product launch delays, inventory shortages, recalls, or unanticipated costs caused by manufacturing problems and capacity imbalances.
• Failure to protect intellectual property rights or to operate without infringing the intellectual property rights of others.
• Failure to generate sufficient cash to service substantial indebtedness.
• Cyberattacks, information security breaches, or other misappropriation of data.
• Governmental laws and regulations affecting domestic and foreign operations, including delays from federal workforce reductions or new tax laws.

Future Outlook

The company is currently evaluating the impact of recently issued accounting standards (ASU No. 2025-07, ASU No. 2025-06, ASU No. 2024-03) on its consolidated financial statements. The One Big Beautiful Bill Act (OBBBA) is not expected to materially impact financial results, effective tax rate, or deferred tax assets and liabilities in 2025 and future periods. Management believes current cash, operating cash flows, and existing financing arrangements will be sufficient to meet liquidity needs for the foreseeable future, while continuously monitoring market conditions.

Management Comments

• Our investments in one of the industry's largest sales organizations, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers.
• Our research and development (R&D) efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so that they remain relevant for our customers.
• The diversity of our product portfolio and our global operations provides stability to our overall business.
• Regarding the IRS audit, we disagree with the IRS position and will defend our position taken on the 2018 U.S. Federal Income Tax return, believing the amount previously accrued remains appropriate.
• We believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the next twelve months and beyond.

Industry Context

Zoetis is a global leader in the animal health industry, specializing in medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health. The companion animal sector's growth is fueled by economic development, increased disposable income, rising pet ownership, and advancements in veterinary medicine. The livestock sector benefits from global population growth and increasing living standards, driving demand for animal protein, enhanced productivity, and focus on food quality and safety. The company operates in a highly regulated environment and is a market leader in most major regions, with a strong presence in emerging markets like Brazil, Chile, China, and Mexico.

Comparison to Industry Standards

• The company identifies key competitors in the animal health field as Elanco, Merck AH, Ceva, Boehringer Ingelheim, Dechra, Virbac, Idexx, and Mars Petcare.
• Zoetis states it is a market leader in nearly all major regions where it operates.
• The company believes it is one of the largest animal health medicines and vaccines businesses by revenue across emerging markets as a whole.

Management Changes

Legal Proceedings

• **Ulianopolis, Brazil Environmental Claim**: A complaint filed in February 2012 by the Municipality of Ulianopolis against Fort Dodge Sade Animal Ltda. (a Zoetis entity) and five other companies, alleging environmental impacts from waste at an incineration facility. The Municipality seeks cleanup costs and compensatory damages. Phase II environmental testing began in October 2024, and parties are collaborating on a waste removal plan.
• **IRS Income Tax Audit**: The company is under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. The IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax for 2018, proposing an additional tax liability of approximately $450 million (excluding interest and penalties). The company disagrees with the IRS position and intends to defend it.
• **OFAC Voluntary Disclosure**: In December 2020, the company submitted a voluntary disclosure to OFAC and the U.S. Department of Justice regarding transactions involving sales of humanitarian animal health products to individuals or entities in or with ties to Iran. In July 2023, OFAC provided a 'No Action' letter, and no further communication from the Department of Justice is anticipated.

Stakeholder Impact

• **Shareholders**: Positive impact from increased net income and EPS, ongoing share repurchase program ($4.5 billion remaining), and consistent dividend payments ($1.000 per share declared for nine months 2025). Potential negative impact from the unresolved IRS tax dispute ($450 million proposed liability).
• **Employees**: Impacted by restructuring charges related to workforce reductions and site closings. Share-based compensation awards continue. Leadership change in R&D with Dr. Polzer's retirement and Dr. Esch's appointment.
• **Customers**: Benefit from a diversified product portfolio and ongoing R&D efforts. Potential impact from tariffs and trade protection measures affecting product costs or demand.
• **Suppliers**: Potential impact from supply chain disruptions, availability constraints, and price volatility of materials.
• **Creditors**: Impacted by the issuance of new senior notes ($1.85 billion) and the redemption of existing notes, as well as the new revolving credit facility. The company remains in compliance with financial covenants.

Next Steps

• Dr. Kevin Esch will succeed Dr. Robert J. Polzer as Executive Vice President and President, Research and Development, effective January 1, 2026.
• Dr. Polzer will remain employed as a non-executive officer through February 28, 2026, to assist in the transition of his duties.
• Dr. Polzer will serve as a non-employee Scientific Advisor from March 1, 2026, through December 31, 2026.
• Kristin Peck's pre-arranged trading plan includes stock sales and gifting between January 2, 2026, and December 31, 2026.
• The company will continue to evaluate the impact of new accounting standards (ASU No. 2025-07, ASU No. 2025-06, ASU No. 2024-03) on its consolidated financial statements.
• Ongoing monitoring of tariffs, trade protection measures, and global economic conditions will continue.
• The company will continue to evaluate the adequacy of its tax reserve as the IRS audit for tax years 2017 and 2018 progresses.
• Collaboration with the prosecutor, Municipality, and technical teams will continue to develop a plan for waste removal and disposal at the Ulianopolis, Brazil site following Phase II testing.

Key Dates

Recommendation

Zoetis demonstrates consistent profitability and strategic capital management, including a substantial share repurchase program and successful debt refinancing. The growth in companion animal products is a strong positive, offsetting some declines in livestock due to the MFA divestiture. However, the modest overall revenue growth, ongoing foreign exchange headwinds, and the significant, unresolved IRS tax dispute introduce a degree of uncertainty. While the company's fundamentals are sound, these factors suggest a 'Hold' position until there is more clarity on revenue acceleration and the resolution of the tax contingency. The executive change in R&D is also a factor to monitor for future innovation pipeline.

Keywords

Animal Health, Pharmaceuticals, Vaccines, Diagnostics, Companion Animals, Livestock, SEC Filing, 10-Q, Financial Results, Zoetis, ZTS, Revenue, Net Income, EPS, Share Repurchase, Debt, R&D, Corporate Governance, Risk Management, Global Markets, Regulatory Compliance